Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up
Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up
复制标题
DOI：
10.2337/dc20-1809
复制
发表时间：
2021-03-01
期刊：
影响因子：
16.2
通讯作者：
Penfornis, Alfred
中科院分区：
文献类型：
--
作者：
Amadou, Coralie;Franc, Sylvia;Penfornis, Alfred
目的分析diabelloop Generation 1 （DBLG1）混合型闭环人工胰腺系统在1型糖尿病患者中的安全性和有效性。研究设计与方法25例患者在使用常规泵1周后，接受商用DBLG1系统。结果在6个月的时间范围（TIR）和HbA（1c）上显示。结果患者平均（SD; range）年龄为43岁（13.8;25-72）岁。基线时，平均HbA（1c）和TIR 70-180 mg/dL分别为7.9% (0.93;5.6-8.5%)[63 mmol/mol (10; 38-69 mmol/mol)]和53%（16.4;21-85%）。一名患者在2个月后停止使用该系统。6个月时，平均HbA（1c）降至7.1% [54 mmol/mol] (P < 0.001)， TIR 70-180 mg/dL升高至69.7% （P < 0.0001）。行动
OBJECTIVE To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions. RESEARCH DESIGN AND METHODS After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA(1c) over 6 months. RESULTS The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA(1c) and TIR 70-180 mg/dL were, respectively, 7.9% (0.93; 5.6-8.5%) [63 mmol/mol (10; 38-69 mmol/mol)] and 53% (16.4; 21-85%). One patient stopped using the system after 2 months. At 6 months, the mean HbA(1c) decreased to 7.1% [54 mmol/mol] (P < 0.001) and TIR 70-180 mg/dL increased to 69.7% (P < 0.0001). TIR